Cunha et al. reported a 2-phase pilot study of CBD versus placebo in normal volunteers and patients with refractory secondarily generalized epilepsy (14). In the first phase, 8 normal volunteers received CBD or placebo in a doubled-blind fashion, at a dose of 3 mg/kg for 30 days. The second phase was also double-blinded in 15 patients with epilepsy receiving 200 to 300 mg daily of CBD or placebo for 135 days. Patients continued baseline AED. All subjects tolerated CBD well, with no serious adverse events. Four of the epilepsy patients receiving CBD were “almost free of convulsive crisis” for the duration of the study. Three other patients receiving CBD had a partial reduction in seizures, and 1 subject had no response. Of the 7 patients receiving placebo, seizure frequency was unchanged in 6, and 1 had clear improvement in seizure control.
Cannabidiol, more commonly known as CBD, is one of 113 known cannabinoids found in cannabis. But unlike its better-known counterpart THC (tetrahydrocannabinol), responsible for cannabis’ mind-altering effects, extensive research suggests that CBD is not psychoactive, and with none of the often-damaging side effects accompanying synthetic pharmaceuticals.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
We have receptors for cannabinoids in the whole body, but the first type (CB1) are very dense in the pain pathways of the brain, spine, and nerves. The second type (CB2) are more important for the immune system but is also involved in inflammation. By gently acting on both pathways, our internal cannabinoids and CBD can balance both pain and inflammation .
Researchers at the Department of Pharmacognosy, The School of Pharmacy, University of London, UK, basis the study conducted on mice found that CBD oil has analgesic properties and may relieve chronic pain of all kinds . It can disrupt the activity of pain receptors in the body and instead cause a release of neurotransmitters such as serotonin and dopamine – “feel good” compounds that can ease discomfort and pain, even if the pharmaceutical painkillers have no effect.
Is CBD Legal? Marijuana-derived CBD products are illegal on the federal level, but are legal under some state laws. Hemp-derived CBD products (with less than 0.3 percent THC) are legal on the federal level, but are still illegal under some state laws. Check your state's laws and those of anywhere you travel. Keep in mind that nonprescription CBD products are not FDA-approved, and may be inaccurately labeled.
The interest and preference for botanical remedies such as CBD oil over harsh pharmaceuticals are growing rapidly. You can read scientific research on the promise of CBD Oil at NCBI. While North America is taking the lead legalizing cannabis and hemp the rest of the world is starting to question their stance on prohibition because of the undeniable benefits. While all talk about plant-based remedies may seem very new, using cannabis/hemp tinctures as a holistic remedy is a generations-old tradition. It was very common to use tinctures of cannabis oil in the eighteenth and nineteenth centuries. We are enjoying a renaissance in ancestral health where we are open again to remedies that were all but forgotten about in the mad race to make medicines a pill offered by a faceless often unaccountable corporation.